🟢 Novanta is trading 4.49% up in pre-market after strong Q2 earnings and raised 2026 guidance

Novanta is trading 4.49% up at $160.00 after second-quarter results beat expectations.

• Revenue reached $265.8 million, while adjusted EPS was $0.89 versus an estimated $0.83.
• Organic growth accelerated to 9.3%.
• Management raised full-year 2026 guidance to revenue of $1.13 billion-$1.14 billion and adjusted EPS of $3.68-$3.74; the Riverpoint Medical acquisition and stronger recurring medical-consumables strategy add support to the bullish outlook.